Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Memphasys Ltd ( (AU:MEM) ) has issued an update.
Memphasys Limited has lodged regulatory submissions for its Felix™ System with Australia’s Therapeutic Goods Administration and India’s Central Drugs Standard Control Organisation, expecting Australian approval by April 2026 and an Indian decision in about six months, leveraging existing CE Mark certification. In parallel, the company is advancing steps to enable immediate commercial sales of Felix™ in the United Kingdom under the current CE Mark-based transition framework, positioning itself to capitalise on sizeable ART and IVF markets in Australia, India and the UK, where approval and registration milestones are described as the final hurdles before full commercial rollout and activation of pending contracts.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian medical technology company focused on assisted reproductive technologies, developing and commercialising the Felix™ System, a device aimed at improving sperm selection and efficiency in in vitro fertilisation (IVF) and related ART procedures across key global fertility markets.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.44M
For an in-depth examination of MEM stock, go to TipRanks’ Overview page.